-
Posted by
Two Blokes May 4 -
Filed in
Stock
-
3 views
Amgen reported strong Q1 results with a 9% YoY revenue increase and a 24% rise in operating EPS, but shares dipped due to risk-on market sentiment. Despite competitive pressures and softer EPS trends, Amgen remains undervalued with a high dividend yield of 3.39% and robust free cash flow. Key risks include emerging therapies and macroeconomic factors, but positive Phase III data and new product launches support a buy-the-dip strategy.
